ClinicalTrials.gg
RecruitingNCT05281757COSINEUpdated Jun 2, 2026

Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Complex

An observational study in Hyperkyphosis, Hyperlordosis and Congenital Scoliosis, sponsored by Aesculap AG. Recruiting at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Aesculap AG (part of B. Braun) · Observational

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

Multicenter, multinational Post-Market Clinical Follow-Up (PMCF) study on the safety and performance of Ennovate® Complex - A prospective, pure data collection of all Ennovate® scoliosis patients in selected centers (not interventional, multicentric)

Read the detailed description

This clinical study is one of the Post-Market Clinical Follow-Up (PMCF) measures that enables the manufacturer to monitor the clinical safety and performance of the Ennovate® Complex system.

The study enables a quick, but detailed implant documentation, which is of great interest for the current and future users of the internal fixation system targeted in this study. It includes the relevant outcomes to evaluate safety and efficacy of the implant system for various indications in deformity disorders.

02

Conditions studied

  • Hyperkyphosis
  • Hyperlordosis
  • Congenital Scoliosis
  • Neuromuscular Scoliosis
  • Idiopathic Scoliosis

Browse trials for

Keywords

  • upper-thoracic spine
03

In context

Kyphosis

132 studies on the registry are indexed under Kyphosis; 31 are open to participants now.

This study's planned enrollment of 200 is above the median of 62 across 45 observational studies indexed under Kyphosis.

Browse Kyphosis studies →

Lead sponsor

Aesculap AG is the lead sponsor of 105 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients who are treated with the Ennovate® Complex system system in accordance with the indications given in the instructions for use: Hyper- / hypokyphosis, Hyper- / hypolordosis, Scoliosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • in the documentation of clinical and radiological results of patients who are minimum 18 years old
  • Informed consent in the documentation of clinical and radiological results of patients AND legal representative (parent) for patients who are younger than 18
  • Patient's indication according to IFU
  • Patient is not pregnant

Exclusion criteria

Exclusion Criteria:

  • Patient's clear unability or unwillingness to participate in follow-up examinations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ennovate® Complex

    All patients who are treated with the Ennovate® Complex system in accordance with indications given in the instructions for use (IFU)

    Device: posterior stabilization for the cervical spine

Interventions

  • Deviceposterior stabilization for the cervical spine

    The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.

06

What researchers measure

Primary outcomes

  1. Change of Pain

    ain will be assessed by the patient using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "maximal / worst pain".

    Time frame: preoperatively, at 3-4 months postoperatively and at approximately 12 and 24 months postoperatively

Secondary outcomes

  1. Change of Quality of Life

    In order to analyze the quality of life of the patients, the most current questionnaire of the Scoliosis Research Society (SRS), the "SRS-30" is used. The SRS-30 demonstrates how spinal conditions impact quality of life and facilitate comparisons of the quality of life before and after surgical intervention. It is widely used in the evaluation of the treatment of idiopathic scoliosis patients. SRS-30 is a patient self administered questionnaire and has a minimum score of 30 and a maximum score of 150 including postsurgery questions. Each question is scored on 1-5 scale. Questions are sorted into different domains and total and mean scores for each domain are calculated. A total score for the entire questionnaire is also calculated.

    Time frame: preoperatively, at 3-4 months postoperatively and at approximately 12 and 24 months postoperatively

  2. Change of Every day life

    Clinical Results measured by Oswestry Disability Index (ODI). ODI contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel, each topic category is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. Each question is scored on a scale of 0 (indicating the least amount of disability) to 5 5 (indicating most severe disability). The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.

    Time frame: preoperatively, at 3-4 months postoperatively and at approximately 12 and 24 months postoperatively

  3. Bone Fusion

    After Complex stabilization fusion of the treated segment is aspired in most cases. The fusion status can be determined from radiographs (static or dynamic). Bony fusion can be characterized quantitatively by the fusion rate.

    Time frame: at final follow-up approximately 24 months after surgery

  4. Cumulative number of Side effects

    Occurrence of complications potentially associated with the implanted devices can never be fully excluded during spinal surgery. In order to monitor potential complication and to identify so far unknown complications Adverse Events and Serious Adverse Events deemed related to the investigational device are recorded.

    Time frame: throughout the follow-up up to 24 months postoperatively

07

Study locations

1 of 2 sites recruiting
  • University Hospital Brno
    Brno, 62500, Czechia
    Suspended

    Not enrolling at this site.

  • Hospital Universiti Kebangsaan Malaysia (HUKM)
    Kuala Lumpur, Malaysia
    Recruiting
    • Mohd Hisam, Prof. Dr. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05281757
Lead sponsor
Aesculap AG
Collaborators
Raylytic GmbH
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Feb 18, 2022
Primary completion
Dec 2026 (estimated)
Completion
Oct 2028 (estimated)
Last update
Jun 2, 2026

Study contacts

Sarah Mattes
Contact
sarah.mattes@aesculap.de
+497461950
Stefan Maenz
Contact
stefan.maenz@aesculap.de
+497461950
Mohd Hisam, Prof. Dr.
principal investigator · Hospital Universiti Kebangsaan Malaysia (HUKM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion